Chemomab Therapeutics Ltd. (NASDAQ:CMMB) went up by 3.68% from its latest closing price compared to the recent 1-year high of $168.80. The company’s stock price has collected 17.23% of gains in the last five trading sessions. Press Release reported 17 hours ago that Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)
Is It Worth Investing in Chemomab Therapeutics Ltd. (NASDAQ :CMMB) Right Now?
Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Chemomab Therapeutics Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $43.50. Today, the average trading volume of CMMB was 268.79K shares.
CMMB’s Market Performance
CMMB stocks went up by 17.23% for the week, with a monthly jump of 11.23% and a quarterly performance of -71.46%, while its annual performance rate touched -2.34%. The volatility ratio for the week stands at 11.54% while the volatility levels for the past 30 days are set at 11.09% for Chemomab Therapeutics Ltd.. The simple moving average for the period of the last 20 days is 12.85% for CMMB stocks with a simple moving average of -35.91% for the last 200 days.
CMMB Trading at -21.71% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.15% of loss for the given period.
Volatility was left at 11.09%, however, over the last 30 days, the volatility rate increased by 11.54%, as shares surge +16.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.51% lower at present.
During the last 5 trading sessions, CMMB rose by +17.23%, which changed the moving average for the period of 200-days by +19.05% in comparison to the 20-day moving average, which settled at $17.86. In addition, Chemomab Therapeutics Ltd. saw -27.75% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CMMB
The total capital return value is set at -111.53, while invested capital returns managed to touch -121.60. Equity return is now at value -54.10, with -46.60 for asset returns.
Based on Chemomab Therapeutics Ltd. (CMMB), the company’s capital structure generated 5.45 points at debt to equity in total, while total debt to capital is 5.17. Total debt to assets is 3.16, with long-term debt to equity ratio resting at 0.45. Finally, the long-term debt to capital ratio is 0.42.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.37.